ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Obituary: Eugene Schonfeld, Founder of Kidney Cancer Foundation

October 3, 1997

The Cancer Letter takes summer publication break, back Sept. 12.

August 8, 2003

NLST Shows 20.3 Percent Mortality Benefit For CT Vs. X-Ray In Lung Cancer Screening

November 5, 2010

In Brief: McDonnell Foundation Selects Five For $400,000 Fellowships; Alberts, Verma Picked For Awards

January 4, 1991

Also in this 8-page issue: David Hohn elected board chairman of the National Comprehensive Cancer Network.

March 26, 2004

Congress Passes FDA User Fee Bill, Averting Layoffs.

September 21, 2007